New therapies for the treatment of type 2 diabetes: an update

C. Day*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


In type 2 diabetes, several lesions have been identified and drugs are being developed that target these lesions. This review considers agents that have been introduced to Europe since 2006, particularly the glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 inhibitors (gliptins) that represent new classes of agent, both of which target the enteroinsular axis. The GLP-1 analogues and gliptins reduce hyperglycaemia without promoting weight gain, with the former being associated with weight loss. Agents advanced in development, new fixed-dose combination tablets and new formulations of established agents are also considered.

Original languageEnglish
Pages (from-to)85-87
Number of pages3
JournalEuropean Diabetes Nursing
Issue number3
Publication statusPublished - 1 Sept 2009


  • DPP-4 inhibitors
  • gliptins
  • GLP-1 analogues
  • SGLT-2 inhibitors
  • type 2 diabetes


Dive into the research topics of 'New therapies for the treatment of type 2 diabetes: an update'. Together they form a unique fingerprint.

Cite this